search icon

    Market Snapshot

    • S&P Futures

      4,132.5

    • Dow Futures

      32,789

    • Nasdaq Futures

      13,103.25

    blog search icon

    Athenex, Inc.

    (NASDAQ:ATNX)

    $1.10

    $0.15

    15.18%

    Athenex, Inc. Chart

    ATNX Stock Price Today

    Athenex, Inc. (ATNX) stock rallied over 15.18% intraday to trade at $1.1 a share on NASDAQ. The stock opened with a gain of 14.35% at $0.94 and touched an intraday high of $1.14, rising 15.18% against the last close of $0.955. The stock went to a low of $0.9 during the session.

    Stock Snapshot

    $0.955

    Prev. Close

    88.23 Million

    Market Cap

    $0.9

    Day Low

    $0.94

    Open

    113.01 Million

    Number of Shares

    $1.14

    Day High

    -

    P/E ratio

    -1.68

    EPS (TTM)

    0.33

    Cash Flow per Share

    2.75

    Free Float in %

    1.39

    Book Value

    4,660,690

    Volume

    Athenex, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-08-08$0.94$1.14$0.9$1.14,660,690
    2022-08-05$0.962$0.996$0.84$0.95513,701,400
    2022-08-04$0.58$0.66$0.58$0.636,619,500
    2022-08-03$0.55$0.623$0.53$0.581522,200
    2022-08-02$0.52$0.55$0.51$0.54444,300
    2022-08-01$0.53$0.53$0.495$0.508259,800
    2022-07-29$0.519$0.54$0.5$0.507200,100
    2022-07-28$0.53$0.535$0.49$0.525537,900
    2022-07-27$0.564$0.59$0.516$0.537472,300
    2022-07-26$0.629$0.636$0.564$0.57391,500

    Contact Details

    Conventus Building
    Suite 600 1001 Main Street
    Buffalo, NY 14203
    United States

    Webiste:ATNX

    716 427 2950

    Company Information

    Employees-

    Beta1.07

    Sales or Revenue120.99 Million

    5Y Sales Change42.4%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

    Frequently Asked Questions

    icon

    What is the current Athenex, Inc. (ATNX) stock price?

    Athenex, Inc. (NASDAQ: ATNX) stock price is $1.1 as of the last check on Monday, August 8. During the trading session, ATNX stock reached the peak price of $1.14 while $0.9 was the lowest point it dropped to.

    icon

    ATNX's industry and sector of operation?

    The NASDAQ listed ATNX is part of Biotechnology industry that operates in the broader Health Care sector. Athenex, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.

    icon

    Who are the executives of ATNX?

    Mr. Steven J. Adams
    Interim Chief Accounting Officer
    Dr. Wing-Kai Chan
    Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms
    Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.
    Chairman & CEO
    Mr. Jeffrey M. Yordon
    COO & Pres of Athenex Pharmaceutical Division

    icon

    What is the ATNX stock price today?

    ATNX stock traded closed the last session at $1.1, which is $0.14500000000000013 or 15.183246073298443% lower than its previous close of $0.955. ATNX's current trading price is 171.54% lower than its 52-week high of $3.91 where as its distance from 52-week low of 0.41% is -71.87%.

    icon

    How many employees does ATNX have?

    Number of ATNX employees currently stands at -. ATNX operates from Conventus Building, Suite 600 1001 Main Street, Buffalo, NY 14203, United States.

    icon

    Link for ATNX official website?

    Official Webiste of $ATNX is: https://www.athenex.com

    icon

    How do I contact ATNX?

    ATNX could be contacted at ATNX operates from Conventus Building, Suite 600 1001 Main Street, Buffalo, NY 14203, United States, or at phone #716 427 2950 and can also be accessed through its website.

    icon

    How many shares of ATNX are traded daily?

    ATNX stock volume for the day was 4,660,690 shares while in the previous session number of ATNX shares traded was 4,660,690 . The average number of ATNX shares traded daily for last 3 months was 1.33 Million.

    icon

    How much did ATNX change today?

    The percentage change in ATNX stock occurred in the recent session was 15.183246073298443% while the dollar amount for the price change in ATNX stock was $0.14500000000000013.

    icon

    What price range ATNX stock been trading in?

    In the recent session, the day high for ATNX stock was $1.14 while the low for ATNX stock touched on the day was $0.9.

    icon

    What is the market cap of ATNX currently?

    The market value of ATNX currently stands at 88.23 Million with its latest stock price at $1.1 and 113.01 Million of its shares outstanding.